| 2024
CV-04 2.4 상위(4.0%)
Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease
Theranostics
CV-04 6.0(상위10.4%)4
"Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders"
European Journal of Medicinal Chemistry
CV-01 6.9 (상위3.5%)
Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis
| 2023
CV-02 6.9 (상위3.5%)
Exploration of Tetrahydroisoquinoline- and Benzo[ c]azepine-Based 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
CV-01 2.4 상위(4.0%)
Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator for the antioxidant and anti-inflammatory effects
| 2022
CV-02 2.4 상위(4.0%)
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis
| 2021
CV-01 6.0(상위10.4%)
Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson’s disease
| 2020
A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model
| 2019
CV-01 6.9(상위3.5%)
Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Erythroid 2
‑Related Factor 2 (Nrf2) Activators for Parkinson’s Disease Therapy
CV-01 3.5
Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator
ACS Medicinal Chemistry Letters
| 2014
Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson’s Disease Therapy
No
게제 연도
논문명
저널명
IF(%)
파이프라인
11
2024
Highly potent and selective PPARδ agonist reverses memory deficits
in mouse models of Alzheimer's disease
2.4 상위(4.0%)
CV-04
10
"Discovery of the therapeutic potential of PPARδ agonist bearing
1,3,4- thiadiazole in inflammatory disorders"
6.0(상위10.4%)
9
Discovery and Optimization of a Series of Vinyl Sulfoximine-Based
Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis
6.9 (상위3.5%)
CV-01
8
2023
Exploration of Tetrahydroisoquinoline- and Benzo[ c]azepine-Based
1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis
CV-02
7
Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator
for the antioxidant and anti-inflammatory effects
6
2022
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists
for the Treatment of Multiple Sclerosis
5
2021
Development and optimization of halogenated vinyl sulfones as
Nrf2 activators for the treatment of Parkinson’s disease
4
2020
A novel chalcone derivative as Nrf2 activator attenuates learning
and memory impairment in a scopolamine-induced mouse model
3
2019
2
3.5
1
2014
Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents
toward Parkinson’s Disease Therapy
Right Structure& Value Creation
저분자 신약 개발의 새로운 역사를 만들다.
ABOUT US
R&D
PIPELINE
INVESTOR
NEWS
CAREERS
CONTACT
주식회사 큐어버스본사: 서울시 성북구 화랑로 14길 5, KIST V1동 212호© 2026 CUREVERSE All rights reserved.
